Advaxis, Incorporated


Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

Tuesday, May 4, 2010

Clinical Trials. gov listing

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ (ADXS11-001)
This study is currently recruiting participants.

Purpose

Cervical cancer is associated with Human Papilloma Virus. About 57% of cervical cancer is the result of infection by Human Papilloma Virus strain 16 (HPV-16). HPV is a very common virus that can affect the cells of the cervix. E7 is a substance that is made by the HPV virus which causes cervical cancer. The purpose of the study is to test the safety, tolerability (how the drug makes you feel), immunology (effects on the immune system) and efficacy (disease curing effects) of a vaccine called Lovaxin C against E7. The vaccine is designed to cause the immune system to react against the E7 substance in a manner that is intended to reverse the changes to the cervix and prevent cervical cancer from occurring

http://www.clinicaltrials.gov/ct2/show/NCT01116245?term=advaxis&rank=1

http://www.clinicaltrials.gov/ct2/show/related/NCT01116245?term=advaxis&rank=1
Posted by at